BeStock  

Neurocrine Biosciences NBIX

US equityMarket cap rank #1096Drug Manufacturers - Specialty & Generic
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–

Earnings

Average move on report day±7.5%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+13.4%
Worst reaction-18.5%

Stock move on the day after each report

-4.7%2023/Q4+4.0%2024/Q1+8.2%2024/Q2+7.0%2024/Q3-18.5%2024/Q4+8.4%2025/Q1-6.2%2025/Q2-6.4%2025/Q3-10.4%2025/Q4+8.9%2026/Q1-10.1%2026/Q2+13.4%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q32 Nov 2026After Market±9.6%+13.42%Bigger than priced
2026/Q230 Jul 2026After Market±8.1%-10.08%Bigger than priced
2026/Q15 May 2026After Market±7.4%+8.86%Bigger than priced
2025/Q411 Feb 2026After Market±6.7%-10.43%Bigger than priced
2025/Q328 Oct 2025After Market±8.9%-6.35%Within range
2025/Q230 Jul 2025After Market±9.2%-6.24%Within range
2025/Q15 May 2025After Market±12.4%+8.36%Within range
2024/Q46 Feb 2025After Market±7.8%-18.53%Bigger than priced
2024/Q330 Oct 2024Pre Market±8.1%+7.01%Within range
2024/Q21 Aug 2024Pre Market±16.3%+8.18%Within range
2024/Q11 May 2024Pre Market±7.3%+3.99%Within range
2023/Q47 Feb 2024Pre Market±7.1%-4.67%Within range
2023/Q331 Oct 2023Pre Market±9.5%+3.56%Within range
2023/Q21 Aug 2023Pre Market±7.5%+1.52%Within range
2023/Q13 May 2023Pre Market±7.8%-4.67%Within range
2022/Q46 Feb 2023Pre Market±8.4%-4.55%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • INGREZZA net product sales$801.50M 71.4%
  • CRENESSITY net product sales$210.80M 18.8%
  • VYKAT XR net product sales$106.70M 9.5%
  • Other revenues$3.70M 0.3%

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.12B+41.2% YoY
Operating profit$343.00M+43.3% YoY
Net profit$206.50M-1.4% YoY
Diluted EPS$1.96-3.9% YoY
Free cash flow$383.60M+79.0% YoY
Operating cash flow$395.20M

Revenue, last 8 quarters

$627.7MDec '24$572.6MMar '25$687.5MJun '25$794.9MSep '25$805.5MDec '25$814.5MMar '26$959.0MJun '26$1.1BSep '26

Net profit, last 8 quarters

$103.1MDec '24$7.9MMar '25$107.5MJun '25$209.5MSep '25$153.7MDec '25$197.9MMar '26$144.4MJun '26$206.5MSep '26

Profitability & balance sheet

Gross margin97.7%
Operating margin24.6%
Net margin19.0%
Return on equity20.4%
Return on assets14.2%
Return on invested capital18.2%
Current ratio2.04
Liabilities / assets31.1%
Cash & investments$737.90M
Total debt$392.30M
Net cash (debt)$345.60M
Free cash flow / sales28.1%

Discussion

No comments yet — be the first to weigh in on NBIX.

Sign in to join the discussion.

Scroll to Top